BTN3A2 and triple-negative breast carcinoma: BTN3A2 is expressed in triple-negative breast cancer, pancreatic ductal carcinoma, and epithelial ovarian cancer, and is associated with a good prognosis (Le Page et al., 2012; Cai et al., 2020).